Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Chapter 9 – Clinical Applications Of Proteomics
Published 2004 · Computer Science, Biology
Save to my Library
Download PDFAnalyze on Scholarcy
Publisher Summary Despite tremendous advances in the understanding of the molecular genetics of diseases, such as cancer, the development of novel diagnostics and therapeutics has lagged behind. Promising areas in disease-related proteomics include the identification of distinctive disease proteomic profiles that correlate with clinical features; the development of novel biomarkers for diagnosis and early detection; the identification of novel targets for therapeutics on the one hand, given that the vast majority of drugs target proteins; and on the other hand, to utilize proteomics to accelerate drug development and evaluation of efficacy and toxicity. The proteome of a cell or a tissue is highly dynamic and changes much more readily in response to external factors than the genome or transcriptome. To capture all the proteomes that a cell or a tissue may manifest in health and disease, represents a substantial challenge for which the current available technologies have a limited reach. There is a need to employ and integrate multiple technologies, as it is unlikely that one technology will address all facets of proteomics. There is also a need to begin an organized international effort in proteomics that brings together investigators in the public as well as private sectors, given the enormity of the task of identifying and characterizing all the proteins in the human proteome. Beyond technological innovations that are required to increase throughput and sensitivity, there is a substantial need to develop informatics tools that allow the mining of proteomic data that will be generated at an unprecedented scale.
This paper references
Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer.
A. Dowlati (1999)
Proteomic approaches to central nervous system disorders.
C. Rohlff (2002)
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
E. Stockert (1998)
Laser capture microdissection.
M. Emmert-Buck (1996)
Proteomics: unraveling the complexity of heart disease and striving to change cardiology.
Van Eyk Je (2001)
Protein microarrays for gene expression and antibody screening.
A. Lueking (1999)
The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy.
T. Soussi (1996)
p53 Antibodies in the sera of patients with various types of cancer: a review.
T. Soussi (2000)
Identification of a lipocalin in mucosal glands of the human tracheobronchial tree and its enhanced secretion in cystic fibrosis.
B. Redl (1998)
Attempts to mimic docking processes of the immune system: recognition-induced formation of protein multilayers.
W. Müller (1993)
Use of a cDNA microarray to analyse gene expression patterns in human cancer
J. DeRisi (1996)
Unlocking the archive – gene expression in paraffin‐embedded tissue
F. Lewis (2001)
Genetic analysis of thirty-three platelet polypeptides detected in two-dimensional polyacrylamide gels.
S. Hanash (1986)
Analysis of yeast protein kinases using protein chips
H. Zhu (2000)
Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection.
B. Schweitzer (2000)
Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.
M. Gourévitch (1995)
An Array Immunosensor for Simultaneous Detection of Clinical Analytes
Chris A. Rowe (1999)
Printing proteins as microarrays for high-throughput function determination.
G. MacBeath (2000)
UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions.
H. Ge (2000)
Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions
B. Haab (2000)
Proteome Analysis—A Novel Approach to Understand the Pathogenesis of Type 1 Diabetes Mellitus
A. E. Karlsen (2001)
Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia.
R. Melhem (1991)
Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3.
A. O. Güre (1998)
Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer
M. Rubin (2001)
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors.
G. Chen (2002)
Phorbol 12-myristate 13-acetate-induced phosphorylation of Op18 in Jurkat T cells. Identification of phosphorylation sites by matrix-assisted laser desorption ionization mass spectrometry.
Y. Wang (1993)
Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species.
X. Zhu (1989)
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front
C. Paweletz (2001)
Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study.
W. Crist (1986)
Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer.
F. Brichory (2001)
Tissue microarrays for high-throughput molecular profiling of tumor specimens
J. Kononen (1998)
Proteomic profiling of the cancer microenvironment by antibody arrays
V. Knezevic (2001)
High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA).
L. Mendoza (1999)
Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma.
T. Hirano (1995)
Modulation of Electroenzymatic NADPH Oxidation through Oriented Immobilization of Ferredoxin:NADP + Reductase onto Modified Gold Electrodes
†. J. Madoz-Gúrpide (2000)
New Paths in Human Cancer Serology
L. Old (1998)
Detection of auto‐antibodies against L‐myc oncogene products in sera from lung cancer patients
A. Yamamoto (1996)
Lung tumor cells: A multivariate approach to cell classification using two‐dimensional protein pattern
H. Schmid (1995)
Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer.
F. Le Naour (2001)
Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children.
S. Hanash (1989)
The Human Proteome Organization
S. Hanash (2002)
Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group.
G. Reaman (1985)
Mass spectrometry and proteomics.
S. Patterson (2000)
Proteomics as the Tool to Search for Lung Disease Markers in Bronchoalveolar Lavage
Isabelle Noël-Georis (2001)
Profiling proteins from azoxymethane‐induced colon tumors at the molecular level by matrix‐assisted laser desorption/ionization mass spectrometry
P. Chaurand (2001)
Mass spectrometry and proteomics.
S. Gygi (2000)
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer.
A. O. Güre (2000)
Identification of β-Tubulin Isoforms as Tumor Antigens in Neuroblastoma
L. Prasannan (2000)
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer
F. Brichory (2001)
Identification of a polypeptide associated with the malignant phenotype in acute leukemia.
S. Hanash (1988)
Primary structure of bovine calpactin I heavy chain (p36), a major cellular substrate for retroviral protein-tyrosine kinases: homology with the human phospholipase A2 inhibitor lipocortin.
T. Kristensen (1986)
Biomedical applications of two‐dimensional electrophoresis using immobilized pH gradients: Current status
S. Hanash (2000)
Proteomics: new perspectives, new biomedical opportunities
R. Banks (2000)
A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis*
F. Le Naour (2002)
Infrequent Presence of Anti-c-Myc Antibodies and Absence of c-Myc Oncoprotein in Sera from Lung Cancer Patients
A. Yamamoto (1999)
Identification of gel‐separated tumor marker proteins by mass spectrometry
A. C. Bergman (2000)
Protein microchips: use for immunoassay and enzymatic reactions.
P. Arenkov (2000)
Profiling Changes in Gene Expression during Differentiation and Maturation of Monocyte-derived Dendritic Cells Using Both Oligonucleotide Microarrays and Proteomics*
F. Le Naour (2001)
Protein based microarrays: A tool for probing the proteome of cancer cells and tissues
J. Madoz-Gúrpide (2001)
Antibody arrays for high-throughput screening of antibody–antigen interactions
R. D. Wildt (2000)
Tissue microarray technology for high-throughput molecular profiling of cancer.
O. Kallioniemi (2001)
High-resolution two-dimensional electrophoresis with isoelectric focusing in immobilized pH gradients.
R. Westermeier (1983)
Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray
M. Schena (1995)
Highly resolving two-dimensional gels for protein sequencing.
S. Hanash (1991)
Immobilization of Antibodies on a Photoactive Self-Assembled Monolayer on Gold
E. Delamarche (1996)
Mass-sensing, multianalyte microarray immunoassay with imaging detection.
J. W. Silzel (1998)
A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library.
K. Büssow (1998)
Plasma proteins of the bronchoalveolar surface of the lungs of smokers and nonsmokers.
D. Y. Bell (1981)